Sanofi is gaining a significant ground in the
bio-tech market Wayrilz, a drug developed by Sanofi, has earned FDA approval becoming the first US BTK drug for immune thrombocytopenia, a rare blood disorder.
Novartis veteran Marcia Kayath has been appointed as Sanofi's Chief Medical Officer following the exit of Dietmar Berger. Sanofi's Sarclisa also received EMA nod for Multiple Myeloma. The company also tapped into digital transformation and Artificial Intelligence, especially in their manufacturing and supply process. However, the company stopped supplying a high cholesterol drug to China citing limited availability. Sanofi's commitment to sustainability and equitability in healthcare has been underlined. Amid legal battles, the company was also able to secure several business deals.
Dupixent, co-developed with Regeneron, continues to impress in treatment studies of multiple diseases while the company continues to spearhead advancements in Genomic Medicine. In an effort to expand production capabilities, Sanofi announces at least $20 billion investment in US manufacturing planned through 2030.
Sanofi News Analytics from Mon, 06 Jan 2025 08:00:00 GMT to Sat, 30 Aug 2025 21:42:01 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor -5
